Gallbladder cancer (GBC): 10‐year experience at Memorial Sloan‐Kettering Cancer Centre (MSKCC)

@article{Duffy2008GallbladderC,
  title={Gallbladder cancer (GBC): 10‐year experience at Memorial Sloan‐Kettering Cancer Centre (MSKCC)},
  author={Austin G. Duffy and Marinela Capanu and Ghassan K. Abou-Alfa and D Huitzil and William R. Jarnagin and Yuman Fong and Michael I D'Angelica and Ronald P. DeMatteo and Leslie H. Blumgart and Eileen M. O’Reilly},
  journal={Journal of Surgical Oncology},
  year={2008},
  volume={98}
}
The incidence of gallbladder cancer (GBC) in the US is 1.2/100,000. This report examines the patterns of presentation, adjuvant treatment and survival of a large cohort of patients with GBC evaluated at MSKCC over a 10‐year period. 

Improvement of clinical outcomes in the patients with gallbladder cancer: lessons from periodic comparison in a tertiary referral center

TLDR
This study was designed to explore the chronologic change of survival outcomes in GBC and prognostic factors and to investigate the role of smoking, diet, and prior history of GBC in this change.

Management of incidental gallbladder cancer in a national cohort

TLDR
The aim of this study was to analyse the management, treatment and survival of patients with incidental gallbladder cancer in a national cohort over a decade.

Evaluation and management of incidental gallbladder cancer.

TLDR
A review of controversies regarding the role of staging, re-resection, and adjuvant treatment for patients with gallbladder cancers in the modern era with the latest published data.

Gall Bladder Cancer.

TLDR
Gallbladder carcinoma is the most common biliary epithelial malignancy and spreads early by lymphatic or hematogenous metastasis and by direct invasion into the liver.

Radical surgery for de novo gallbladder carcinoma—Single‐center analysis of prognostic factors and survival outcomes from an endemic region

TLDR
Survival outcomes in patients with de novo GBC from endemic regions undergoing surgery for curative intent from a region with high incidence of disease are reported.

Clinicopathologic analysis of undifferentiated carcinoma of the gallbladder

TLDR
Undifferentiated carcinoma of the gallbladder (GB) is a rare malignant neoplasm and there have only been sparse case reports without precise description, so its aspects of clinicopathologic characteristics and prognosis are analyzed.

Surgical Management of Gallbladder Cancer

TLDR
This article will summarize the most recent data with regards to the surgical options, and provides an algorithm to manage GB cancer based on T-staging, which will help to achieve better results.

Gallbladder carcinoma: a New Zealand centre's 10‐year experience with presentation, ethnic diversity and survival rate

TLDR
The primary aim was to determine the incidence and characteristics of gallbladder cancer in a New Zealand population, and to determine if inequalities in gallbladders cancer rates between Māori and non‐Māori have decreased.

Incidental Gallbladder Cancer

TLDR
Because of the fatality of GBC and its poor prognosis, attempts of curative surgery are limited to localized resectable disease.

Infiltrative squamous cell carcinoma of the gallbladder: a unique approach to surgical palliation

TLDR
It is hoped that the surgical approach utilized in this case may provide additional insight on treatment options for gallbladder cancer.
...

References

SHOWING 1-10 OF 20 REFERENCES

Management of carcinoma of the gallbladder: A single‐institution experience in 16 years

TLDR
Evaluated the outcome of patients with carcinoma of gallbladder managed in a single institution over 16 years to find out whether radical surgery or chemotherapy is the only curative treatment.

Recent trends of gallbladder cancer in Japan

TLDR
The objective of this study was to determine whether there were any changes over time in the incidence, therapeutic approach, stage at diagnosis, or prognosis of gallbladder cancer in an unselected, community‐based series of patients in Japan.

Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma

TLDR
An in‐depth analysis of the sites of initial recurrence after resection of GBCA and HCCA aimed to highlight differences in the biology of these tumors and to provide further insight for adjuvant therapeutic strategies.

Chemoradiotherapy in gallbladder cancer

TLDR
The lack of valid and scientific evidence means that most of the recommendations originate from trials dealing with other tumors, such as pancreas cancer and biliary tract cancer, and warrant further evaluation focusing on GC.

The National Cancer Data Base report on carcinoma of the gallbladder, 1989‐1995

Reports utilizing data from the Commission on Cancer's National Cancer Data Base (NCDB) have previously contained evaluations of time trends for stage of disease at diagnosis, treatment, and survival

Biliary tract cancers: current concepts and controversies

TLDR
Treatment decisions should be individualised and participation in clinical trials is encouraged, as further progress in the management of biliary tract cancer is anticipated using biological therapies and continued research is essential to discover the optimal treatment for this challenging disease.

A phase II study of gemcitabine in gallbladder carcinoma.

TLDR
In this phase II trial, gemcitabine is an active chemotherapy in metastatic or inoperable gallbladder carcinoma, with a manageable toxicity profile.

Chemotherapy with gemcitabine in patients with advanced gallbladder carcinoma.

TLDR
It is concluded that gemcitabine may be an effective drug in the palliative treatment of gallbladder cancer, and thus its efficiency warrants evaluation in further studies.

Incidental gallbladder cancer diagnosed during and after laparoscopic cholecystectomy.

TLDR
Even when incidental GBC diagnosed with LC is advanced, adequate additional surgery may improve the prognosis, and patients with stage Tis or T1a tumors should undergo systematic liver resection with lymphadenectomy.

A Phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer

TLDR
The present study shows that gemcitabine/cisplatin combination is well tolerated and active in advanced unresectable gall bladder cancer.